{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T18:06:23Z","timestamp":1773425183990,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,13]]},"DOI":"10.7759\/cureus.105182","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:33:16Z","timestamp":1773423196000},"source":"Crossref","is-referenced-by-count":0,"title":["Diagnosis and Management of Synchronous Prostate and Rectal Cancer in a Patient"],"prefix":"10.7759","author":[{"given":"Hamail","family":"Iqbal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilanjan","family":"Haldar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam C","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1308\/003588412X13373405384611","article-title":"Interactions in the aetiology, presentation and management of synchronous and metachronous adenocarcinoma of the prostate and rectum","volume":"94","author":"Nash GF","year":"2012","unstructured":"Nash GF, Turner KJ, Hickish T, Smith J, Chand M, Moran BJ. Interactions in the aetiology, presentation and management of synchronous and metachronous adenocarcinoma of the prostate and rectum. Ann R Coll Surg Engl. 2012, 94:456-62. 10.1308\/003588412X13373405384611","journal-title":"Ann R Coll Surg Engl"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2022.13606","article-title":"Treatment of rectal cancer after previous prostate cancer: a single institution experience","volume":"25","author":"Millican J","year":"2023","unstructured":"Millican J, Wong M. Treatment of rectal cancer after previous prostate cancer: a single institution experience. Oncol Lett. 2023, 25:20. 10.3892\/ol.2022.13606","journal-title":"Oncol Lett"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-022-01282-9","article-title":"Diagnostic pitfalls: a case of prostate cancer and rectal cancer accompanied by prostate cancer invasion of the rectum","volume":"17","author":"Long Q","year":"2022","unstructured":"Long Q, Wu J, Peng Y, Zhang X, Liu X, Chen H. Diagnostic pitfalls: a case of prostate cancer and rectal cancer accompanied by prostate cancer invasion of the rectum. Diagn Pathol. 2022, 17:98. 10.1186\/s13000-022-01282-9","journal-title":"Diagn Pathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2014.12.030","article-title":"Synchronous rectal and prostate cancer--the impact of MRI on incidence and imaging findings","volume":"84","author":"Sturlud\u00f3ttir M","year":"2015","unstructured":"Sturlud\u00f3ttir M, Martling A, Carlsson S, Blomqvist L. Synchronous rectal and prostate cancer--the impact of MRI on incidence and imaging findings. Eur J Radiol. 2015, 84:563-7. 10.1016\/j.ejrad.2014.12.030","journal-title":"Eur J Radiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2340\/1651-226X.2025.42592","article-title":"Rising incidence trends of synchronous prostate and rectal cancers: a population-based study","volume":"64","author":"Edfelt E","year":"2025","unstructured":"Edfelt E, Shahrivar M, Holmsten K, Radkiewicz C. Rising incidence trends of synchronous prostate and rectal cancers: a population-based study. Acta Oncol. 2025, 64:374-9. 10.2340\/1651-226X.2025.42592","journal-title":"Acta Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00345","article-title":"Multi-institutional analysis of synchronous prostate and rectosigmoid cancers","volume":"10","author":"Jacobs CD","year":"2020","unstructured":"Jacobs CD, Trotter J, Palta M, et al.. Multi-institutional analysis of synchronous prostate and rectosigmoid cancers. Front Oncol. 2020, 10:345. 10.3389\/fonc.2020.00345","journal-title":"Front Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20150292","article-title":"The curative management of synchronous rectal and prostate cancer","volume":"89","author":"Lavan NA","year":"2016","unstructured":"Lavan NA, Kavanagh DO, Martin J, et al.. The curative management of synchronous rectal and prostate cancer. Br J Radiol. 2016, 89:20150292. 10.1259\/bjr.20150292","journal-title":"Br J Radiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08683-4","article-title":"Surgical management and outcomes of rectal cancer with synchronous prostate cancer: a multicenter experience from the GRECCAR group","volume":"27","author":"Doussot A","year":"2020","unstructured":"Doussot A, Vernerey D, Rullier E, et al.. Surgical management and outcomes of rectal cancer with synchronous prostate cancer: a multicenter experience from the GRECCAR group. Ann Surg Oncol. 2020, 27:4286-93. 10.1245\/s10434-020-08683-4","journal-title":"Ann Surg Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0051","article-title":"Rectal cancer, version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Benson AB","year":"2022","unstructured":"Benson AB, Venook AP, Al-Hawary MM, et al.. Rectal cancer, version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022, 20:1139-67. 10.6004\/jnccn.2022.0051","journal-title":"J Natl Compr Canc Netw"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1374360","article-title":"Outcomes associated with total neoadjuvant therapy with non-operative intent for rectal adenocarcinoma","volume":"14","author":"Asare E","year":"2024","unstructured":"Asare E, Venner E, Batchelor H, et al.. Outcomes associated with total neoadjuvant therapy with non-operative intent for rectal adenocarcinoma. Front Oncol. 2024, 14:1374360. 10.3389\/fonc.2024.1374360","journal-title":"Front Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01208","article-title":"Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial","volume":"42","author":"Verheij FS","year":"2024","unstructured":"Verheij FS, Omer DM, Williams H, et al.. Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial. J Clin Oncol. 2024, 42:500-6. 10.1200\/JCO.23.01208","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA2","article-title":"PROSPECT: a randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (alliance N1048)","volume":"41","author":"Schrag D","year":"2023","unstructured":"Schrag D, Shi O, Weiser MR, et al.. PROSPECT: a randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (alliance N1048). J Clin Oncol. 2023, 41:LBA2. 10.1200\/JCO.2023.41.17_suppl.LBA2","journal-title":"J Clin Oncol"},{"key":"ref14","article-title":"Prostate Cancer Treatment (PDQ\u00ae): Health Professional Version","author":"PDQ Adult Treatment Editorial Board","year":"2002","unstructured":"PDQ Adult Treatment Editorial Board. Prostate Cancer Treatment (PDQ\u00ae): Health Professional Version. National Cancer Institute, Bethesda, MD; 2002. https:\/\/pubmed.ncbi.nlm.nih.gov\/26389471\/."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807801","article-title":"Radical prostatectomy or watchful waiting in prostate cancer - 29-year follow-up","volume":"379","author":"Bill-Axelson A","year":"2018","unstructured":"Bill-Axelson A, Holmberg L, Garmo H, et al.. Radical prostatectomy or watchful waiting in prostate cancer - 29-year follow-up. N Engl J Med. 2018, 379:2319-29. 10.1056\/NEJMoa1807801","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy FC","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA, et al.. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023, 388:1547-58. 10.1056\/NEJMoa2214122","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6941a1","article-title":"Prostate cancer incidence and survival, by stage and race\/ethnicity - United States, 2001-2017","volume":"69","author":"Siegel DA","year":"2020","unstructured":"Siegel DA, O'Neil ME, Richards TB, Dowling NF, Weir HK. Prostate cancer incidence and survival, by stage and race\/ethnicity - United States, 2001-2017. MMWR Morb Mortal Wkly Rep. 2020, 69:1473-80. 10.15585\/mmwr.mm6941a1","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000049","article-title":"ACR Appropriateness Criteria\u00ae definitive external-beam irradiation in stage T1 and T2 prostate cancer","volume":"37","author":"Nguyen PL","year":"2014","unstructured":"Nguyen PL, Aizer A, Assimos DG, et al.. ACR Appropriateness Criteria\u00ae definitive external-beam irradiation in stage T1 and T2 prostate cancer. Am J Clin Oncol. 2014, 37:278-88. 10.1097\/COC.0000000000000049","journal-title":"Am J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/jmrs.143","article-title":"Synchronous prostate and rectal adenocarcinomas irradiation utilising volumetric modulated arc therapy","volume":"62","author":"Ng SP","year":"2015","unstructured":"Ng SP, Tran T, Moloney P, Sale C, Mathlum M, Ong G, Lynch R. Synchronous prostate and rectal adenocarcinomas irradiation utilising volumetric modulated arc therapy. J Med Radiat Sci. 2015, 62:286-91. 10.1002\/jmrs.143","journal-title":"J Med Radiat Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/s0090-4295(00)01126-2","article-title":"External beam radiotherapy for synchronous rectal and prostatic tumors","volume":"57","author":"Siu W","year":"2001","unstructured":"Siu W, Kapp DS, Wren SM, King C, Terris MK. External beam radiotherapy for synchronous rectal and prostatic tumors. Urology. 2001, 57:800. 10.1016\/s0090-4295(00)01126-2","journal-title":"Urology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2016.04.015","article-title":"Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: a secondary analysis of RTOG 94-08 and 96-01","volume":"34","author":"Mak RH","year":"2016","unstructured":"Mak RH, Hunt D, Efstathiou JA, et al.. Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: a secondary analysis of RTOG 94-08 and 96-01. Urol Oncol. 2016, 34:430.e1-7. 10.1016\/j.urolonc.2016.04.015","journal-title":"Urol Oncol"},{"key":"ref22","article-title":"Late toxicity rates following definitive radiotherapy for prostate cancer","volume":"19","author":"Ohri N","year":"2012","unstructured":"Ohri N, Dicker AP, Showalter TN. Late toxicity rates following definitive radiotherapy for prostate cancer. Can J Urol. 2012, 19:6373-80.","journal-title":"Can J Urol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/400320-diagnosis-and-management-of-synchronous-prostate-and-rectal-cancer-in-a-patient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:33:17Z","timestamp":1773423197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/400320-diagnosis-and-management-of-synchronous-prostate-and-rectal-cancer-in-a-patient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.105182","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,13]]}}}